Vera P. Vavilova

Vera P. Vavilova

Auto-generated profile, based on publicly available information

Vera P. Vavilova

Kemerovo State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2024 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
STSofya A. Tsarkova
Sofya A. Tsarkova
OZOlga V. Zaytseva
Olga V. Zaytseva
ELEvelina Lokshina
Evelina Lokshina
SZSvetlana V. Zaytseva
Svetlana V. Zaytseva
EIElena P. Isaeva
Elena P. Isaeva
ХЮХалидуллина Оксана Юрьевна
Халидуллина Оксана Юрьевна
Background. Currently, there are no multicenter studies to determine the prevalence and incidence of symptoms of post-COVID syndrome (PCS) in children in different age groups, to develop consistent observation algorithms, and to identify therapy options. Aim. To establish the risk factors for PCS in children and its CSs in the Russian Federation. Materials and methods. A retrospective multicenter cross-sectional study was conducted. The initial stage of the study included 565 children at 7.6±0.17 months after the new coronavirus infection (NCVI) who were on outpatient or inpatient observation in different regions of Russia from November 2022 to May 2023. Patients were selected from 9 regions of the Russian Federation, such as Izhevsk, Kemerovo, Moscow, Omsk and Omsk region, Yekaterinburg and Sverdlovsk region, Ufa, Tyumen, Samara, Naberezhnye Chelny. All patients were offered a questionnaire. The questionnaire was developed and adapted based on the British and American consensus on the PCS, which included an assessment of the history, severity of the disease, clinical form of acute NCVI, therapy in the acute period of NCVI, and the presence of comorbidities. In addition, the course of acute NCVI and symptoms 3 months after the disease were evaluated by the following groups of CS: asthenia, respiratory disorders (RD), gastrointestinal disorders (GI), neurocognitive disorders (NCD), skin/adnexal lesions, olfactory/taste disorders, autonomic dysfunction (AD), anxiety. Of the 565 questionnaires received, 435 (76.9%) met the inclusion criteria and were available for subsequent analysis. The mean age was 9.0±0.25 years. Results. During the acute period of the NCVI, asthenic syndrome (AS), RD and NCD, anxiety symptoms, olfactory/taste disorders, manifestations of AD, GI and skin/adnexal lesions were most often detected. Our study showed that after 3 months or more after NKVI, AS, NCD, and RD recurred in almost half of the observed children (53.1, 49.0 and 47.8%, respectively), anxiety was detected in 42,5% of cases, in more than 1/5 of children, AD, olfactory/taste and gastrointestinal disorders, in 14.3% skin/appendage lesions. Even 90 days after recovery from NCVI, more than half of patients reported impaired functionality, and most children had multiple complaints, which significantly impaired their quality of life. The risk of developing certain manifestations of PCS was increased in patients with comorbidities. Conclusion. The study found that PCS developed in patients with severe, moderate, and mild acute COVID-19. The presence of comorbidities (allergic, neurological diseases, ENT disorders) statistically significantly increased the risk of PCS. The study's results further confirm the importance of continuous monitoring of NKVI sequelae in children and adolescents and the need for follow-up in children recovered from NKVI for 3-12 months.

30 July 2022 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
VVVera P. Vavilova
Vera P. Vavilova
AVAleksandr M. Vavilov
Aleksandr M. Vavilov
ACAsia Kh. Cherkaeva
Asia Kh. Cherkaeva
INIrina A. Nechaeva
Irina A. Nechaeva
Background. Acute upper respiratory tract infections (AURTIs) are common in children and can become recurrent, especially in patients with pharyngeal and/or palatine tonsil disorders. Aim. To evaluate the efficacy and safety of the herbal medicine of marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark and dandelion herb (Tonsilgon N) in preschool children with adenotonsillar disorders. Materials and methods. The study included 1876 children aged 2 to 5 years with a history of pharyngeal and/or palatine tonsil disorders and frequent recurrent respiratory infections. The subjects were randomized into two groups: Group 1 (n=940) received herbal medicine (10 drops 56 times daily) for 30 days, and Group 2 (n=936) received no additional medication. Efficacy and safety were evaluated after the therapy course and during the follow-up (3, 6, and 12 months after the treatment started). The assessment included nasopharyngeal endoscopy, cytological examination of nasal mucosa smears, measurement of soluble immunoglobulin A (sIgA) levels and lysozyme activity in nasal secretion. Results. After a course of therapy, a significant decrease in the incidence of AURTIs (p0.05), associated with a local immunity improvement, estimated by sIgA levels and lysozyme activity (p0.001 for both values versus the control group), was noted. By the end of the study, in 86.5% of patients of Group 1, the pharyngeal tonsil volume decreased from grade 2 to grade 1 of hypertrophy (p=0.000). The pharyngeal and palatine tonsil hypertrophy worsened in 83.6% of Group 2 patients. Conclusion. The study results showed that Tonsilgon N significantly reduced the incidence of AURTIs in children with pharyngeal and/or palatine tonsil disorders and frequent recurrent respiratory infections. This effect was associated with an increase in sIgA and lysozyme levels in the nasal secretion and a decrease in neutrophil counts, indicating an improvement in local immunity.

18 January 2023 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
VVVera P. Vavilova
Vera P. Vavilova
AVAlexander M. Vavilov
Alexander M. Vavilov
STSofya A. Tsarkova
Sofya A. Tsarkova
ONOlga L. Nesterova
Olga L. Nesterova
AKAleksandra A. Kulyabina
Aleksandra A. Kulyabina
ДАДобряк Татьяна Александровна
Добряк Татьяна Александровна
Background. The issue of acute respiratory infections in children remains one of the most urgent. Therefore, in the pandemic due to the new coronavirus SARS-CoV-2, the search for effective treatment regimens for this disease is necessary. Aim. To compare the change of clinical symptoms, terms of virus elimination and disease-related economic cost as well as utilization of outpatient healthcare services in children with new coronavirus infection using the herbal medicine Tonsilgon N, oral solution, added to standard therapy. Materials and methods. A prospective open comparative cohort study of the effectiveness of coronavirus infection treatment in children using the standard of care alone and the standard of care with Tonsilgon N was conducted. Group 1 children (n=720) received the standard therapy for COVID-19 and Tonsilgon N oral solution for 10 days, and group 2 patients (n=670) only received the standard therapy for COVID-19. Treatment efficacy was evaluated according to the change of clinical symptoms in the observed patients, the results of SARS-CoV-2 coronavirus RNA detection in nasopharyngeal smears by polymerase chain reaction, the utilization of healthcare services, temporary disability of parents, the economic cost of the disease. Results. Studied patients of both groups had a typical clinical presentation of mild to moderate severity new coronavirus infection. Fatigue (96.599.7%) and sore throat (93.893.9%) were the most frequent symptoms. Posterior pharynx hyperemia was noted slightly less frequently. Low-grade fever was noted in 85.786.6% of the patients, equally often in patients of both groups. The significant therapeutic effect of the herbal medicine containing extract of marshmallow root, chamomile flowers, horsetail herb, walnut leaf, yarrow herb, oak bark, and dandelion herb includes reducing the time of sore throat relief in 93.2% of main group patients. After 10 days of treatment, sore throat persisted only in 6.8% of group 1 and 68.1% of group 2 patients (p=0.0001). These results indicate that Tonsilgon combined with standard of care is a promising way to improve the quality of life of children with the new coronavirus infection. The addition of Tonsilgon in therapy for new coronavirus infection in children shortens the time of acute inflammation resolution and reduces the duration of inflammatory intoxication. The therapy of new coronavirus infection under the provisional guidelines leads to a reduction in the time for clinical recovery and virus elimination in children and adolescents (p=0.0001) and a decrease in the utilization of outpatient healthcare services are observed: 3/4 of Group 1 patients and 1/2 of Group 2 patients (p=0.0001) applied for medical help twice during the observation period, 14.6% of Group 1 patients and 29.1% of Group 2 parents applied for medical help more than 3 times (p=0.0001). Thus, the direct and indirect economic costs of the disease decreased. The lower economic cost for parents of children in Group 1 was due to less need for medication and a lower reduction in family income due to temporary disability compared to those for parents in Group 2 (p=0.0001). No treatment-related adverse events was reported. Conclusion. The above data indicate that Tonsilgon therapy is an affordable way to optimize the treatment of new coronavirus infection in children.

26 September 2022 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
VVVera P. Vavilova
Vera P. Vavilova
AVAlexander M. Vavilov
Alexander M. Vavilov
STSofya A. Tsarkova
Sofya A. Tsarkova
ЦАЦарькова Софья Анатольевна
Царькова Софья Анатольевна
Background. Acute respiratory infections (ARI) in pediatric practice remain one of the most relevant problems, therefore, it is necessary to search for effective prevention schemes in terms of pandemic caused by the new SARS-CoV-2 coronavirus. Aim. To evaluate preventive effect of one of the Polyoxidonium drug regimens in respect to SARS, influenza and COVID-19, compared with the absence of drug prophylaxis in children attending children's organized groups. Materials and methods. A prospective open comparative cohort study of the effectiveness of Polyoxidonium used as a preventing treatment against acute respiratory viral infections (ARVI), influenza and coronavirus infection in children attending organized groups was carried out. In the 1st group children (n=300) received Polyoxidonium 1/2 tablet of 12 mg once a day for 7 days, then 21 days drug-free interval (3 courses over a period of 3 months), in the 2nd group children (n=300) received Polyoxidonium 1/2 tablet of 12 mg 1 time per day for 10 days, then 4 days drug-free interval (6 courses over a period of 3 months), group 3 (n=300) control children did not receive prophylactic drugs. The effectiveness of prevention regimen was assessed using morbidity rate and changes in sIgA and lysozyme activity in the nasal secretion. Results. In the active groups with Polyoxidonium treatment a significant decrease in the number of cases of ARI and COVID-19 was recorded compared with the control group. The beneficial effect of the preventive use of Polyoxidonium on the likelihood of developing ARVI, COVID-19 and their clinical course was more significant in group 2 (p=0.0001) than in group 1. A positive preventive effect of Polyoxidonium on the development of ARVI, COVID-19 and their clinical course in group 1 was noted when compared to the control group (p=0.0001). In group 2, none of the participants developed pneumonia, while in group 1 one case of pneumonia was registered, and in the control group pneumonia was noted in seven children (2.3%); p=0.0327, 0.0078. The use of Polyoxidonium led to a significant increase in local immunity of the mucous membranes of the upper respiratory tract lysozyme and sIgA in groups 1 and 2 [1 group sIgA 0.240.14 g/L (p=0.0085), lysozyme 60.918.53% (p=0.0084); 2 group sIgA 0.240.14 g/L (p=0.0024), lyzozyme 65.016.62% (p=0.0001)]. Conclusion. The use of Polyoxidonium drug as a preventing care for ARI and COVID-19 meets up to date requirements and can serve as an additional protection line against infection in children in organized groups.

1 January 2020 in Russian Journal of Woman and Child Health
Verified
Journal Article
Open access
STS.A. Tsar’kova
S.A. Tsar’kova
ASAnastasiya Sokolova
Anastasiya Sokolova
VVV.P. Vavilova
V.P. Vavilova
Y1Yekaterinburg Children’s City Clinical Hospital No. 11
Yekaterinburg Children’s City Clinical Hospital No. 11

15 December 2024 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
NGNatalia Geppe
Natalia Geppe
AGAleksandr V. Gorelov
Aleksandr V. Gorelov
YLYuri V. Lobzin
Yuri V. Lobzin
OKOl'GA V. Karneeva
Ol'GA V. Karneeva
TCTat'IAna A. Chebotareva
Tat'IAna A. Chebotareva
ИАИльенкова Наталья Анатольевна
Ильенкова Наталья Анатольевна
Every year, a seasonal increase in the incidence of respiratory infections is registered in the Russian Federation, primarily among children. It significantly increases the burden on the outpatient pediatric service. It is especially important to optimize the daily practice of pediatricians by developing algorithms and updating treatment protocols, as well as creating and conducting training programs. Fever is a leading symptom in acute respiratory viral infections and one of the most common reasons for seeking help in outpatient pediatric services. Leading experts in the field of therapy of respiratory infections in pediatrics have repeatedly discussed the problems of management of feverish children with acute respiratory infections, routing, personalized choice of therapy regimens at the outpatient stage of medical care. As a result, a number of positions concerning the individual use of antipyretic drugs in children over 3 years of age were agreed upon, “alarming” symptoms requiring immediate assistance/hospitalization were listed, and an algorithm for prescribing antipyretic therapy in children over 3 years of age was agreed upon.